Prostate cancer and vitamin D: What does the evidence really suggest?

Urologic Clinics of North America

Volumn 38, Issue 3, 2011, Pages 333-342

  Barnett, Christine M ^a   Beer, Tomasz M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Prostate cancer; Supplementation; UV; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANTINEOPLASTIC AGENT; CALCITRIOL; DOCETAXEL; OXYGENASE; PREDNISONE; VITAMIN D; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CALCIUM INTAKE; CANCER CONTROL; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CELL CYCLE ARREST; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION EXPOSURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ULTRAVIOLET RADIATION; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC NEOPLASMS; VITAMIN D; VITAMINS;

EID: 79960636706     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.04.007     Document Type: Review

References (59)

1. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990, 10(5A):1307-1311.
2. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70(12):2861-2869.
3. Luscombe C.J., Fryer A.A., French M.E., et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001, 358(9282):641-642.
4. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94(6):1867-1875.
5. Bodiwala D., Luscombe C.J., French M.E., et al. Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 2003, 24(4):711-717.
6. John E.M., Schwartz G.G., Koo J., et al. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005, 65(12):5470-5479.
7. Schwartz G.G., Hanchette C.L. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 2006, 17(8):1091-1101.
8. Chen T.C., Wang L., Whitlatch L.W., et al. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003, 88(2):315-322.
9. Schwartz G.G., Whitlatch L.W., Chen T.C., et al. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998, 7(5):391-395.
10. Nanes M.S., Kuno H., Demay M.B., et al. A single up-stream element confers responsiveness to 1,25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene. Endocrinology 1994, 134(3):1113-1120.
11. Liu M., Lee M.H., Cohen M., et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996, 10(2):142-153.
12. Guzey M., Kitada S., Reed J.C. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002, 1(9):667-677.
13. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004, 18(5):1109-1119.
14. Hakim I., Bar-Shavit Z. Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem 2003, 88(5):986-998.
15. McGaffin K.R., Chrysogelos S.A. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol 2005, 35(1):117-133.
16. Zhuang S.H., Burnstein K.L. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139(3):1197-1207.
17. Miller G.J., Stapleton G.E., Ferrara J.A., et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992, 52(3):515-520.
18. Skowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993, 132(5):1952-1960.
19. Peehl D.M., Skowronski R.J., Leung G.K., et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994, 54(3):805-810.
20. Oades G.M., Dredge K., Kirby R.S., et al. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 2002, 90(6):607-616.
21. Hsu J.Y., Feldman D., McNeal J.E., et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001, 61(7):2852-2856.
22. Whitlatch L.W., Young M.V., Schwartz G.G., et al. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 2002, 81(2):135-140.
23. Robsahm T.E., Tretli S., Dahlback A., et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004, 15(2):149-158.
24. Lagunova Z., Porojnicu A.C., Dahlback A., et al. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007, 67(12):1362-1370.
25. Ahn J., Albanes D., Peters U., et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007, 16(12):2623-2630.
26. Rodriguez C., McCullough M.L., Mondul A.M., et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 2003, 12(7):597-603.
27. Park Y., Mitrou P.N., Kipnis V., et al. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol 2007, 166(11):1270-1279.
28. Chan J.M., Pietinen P., Virtanen M., et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000, 11(9):859-867.
29. Baron J.A., Beach M., Wallace K., et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 2005, 14(3):586-589.
30. Berndt S.I., Carter H.B., Landis P.K., et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002, 60(6):1118-1123.
31. Tavani A., Gallus S., Franceschi S., et al. Calcium, dairy products, and the risk of prostate cancer. Prostate 2001, 48(2):118-121.
32. Tavani A., Bertuccio P., Bosetti C., et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005, 48(1):27-33.
33. Kristal A.R., Arnold K.B., Neuhouser M.L., et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2010, 172(5):566-577.
34. Kristal A.R., Cohen J.H., Qu P., et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(8):719-725.
35. Chan J.M., Giovannucci E., Andersson S.O., et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998, 9(6):559-566.
36. Giovannucci E., Liu Y., Rimm E.B., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98(7):451-459.
37. Skinner H.G., Schwartz G.G. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2008, 17(9):2302-2305.
38. Tuohimaa P., Tenkanen L., Ahonen M., et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004, 108(1):104-108.
39. Ahn J., Peters U., Albanes D., et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008, 100(11):796-804.
40. Holt S.K., Kwon E.M., Koopmeiners J.S., et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010, 70(13):1448-1460.
41. Mikhak B., Hunter D.J., Spiegelman D., et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 2007, 67(9):911-923.
42. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007, 25(6):669-674.
43. Beer T.M., Eilers K.M., Garzotto M., et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21(1):123-128.
44. Beer T.M., Garzotto M., Katovic N.M. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004, 27(5):535-541.
45. Tiffany N.M., Ryan C.W., Garzotto M., et al. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005, 174(3):888-892.
46. Trump D.L., Potter D.M., Muindi J., et al. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006, 106(10):2136-2142.
47. Chan J.S., Beer T.M., Quinn D.I., et al. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int 2008, 102(11):1601-1606.
48. Giovannucci E., Rimm E.B., Wolk A., et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998, 58(3):442-447.
49. Corder E.H., Guess H.A., Hulka B.S., et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993, 2(5):467-472.
50. Ahonen M.H., Tenkanen L., Teppo L., et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11(9):847-852.
51. Li H., Stampfer M.J., Hollis J.B., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007, 4(3):e103.
52. Braun M.M., Helzlsouer K.J., Hollis B.W., et al. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995, 6(3):235-239.
53. Gann P.H., Hennekens C.H., Hollis B.W., et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996, 5(2):121-126.
54. Nomura A.M., Stemmermann G.N., Lee J., et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998, 9(4):425-432.
55. Platz E.A., Leitzmann M.F., Hollis B.W., et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004, 15(3):255-265.
56. Jacobs E.T., Giuliano A.R., Martínez M.E., et al. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004, 89-90(1-5):533-537.
57. Faupel-Badger J.M., Diaw L., Albanes D., et al. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 2007, 16(12):2784-2786.
58. Travis R.C., Crowe F.L., Allen N.E., et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 2009, 169(10):1223-1232.
59. Barnett C.M., Nielson C.M., Shannon J., et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010, 21(8):1297-1303.